ArticleAntimicrobial agents and chemotherapy2014
Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 67 citations in OpenAlex.
- Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions inGut microbes · 2025Article
- A Literature Review on the Impact of the Gut Microbiome on Cancer Treatment Efficacy, Disease Evolution and Toxicity: The Implications for Hematological Malignancies.Journal of clinical medicine · 2025Review
- Relationship between periodontitis and chronic obstructive pulmonary disease: a bibliometric analysis from 1945 to 2023.Medicina oral, patologia oral y cirugia bucal · 2025Article
- Clinical use of tigecycline may contribute to the widespread dissemination of carbapenem-resistant hypervirulentEmerging microbes & infections · 2024Article
- Polyvalent Bacterial Lysate with Potential Use to Treatment and Control of Recurrent Urinary Tract Infections.International journal of molecular sciences · 2024Article
- Biofilm Formation ofMicroorganisms · 2023Review
- Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin.The Journal of antimicrobial chemotherapy · 2023Article
- The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.Applied microbiology and biotechnology · 2022Article
- Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis andFrontiers in microbiology · 2022Article
- Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea.Current opinion in biotechnology · 2020Review
- Article
- Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.Antimicrobial agents and chemotherapy · 2018Article
- Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria.PLoS pathogens · 2018Article
- Article
- Article
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.World journal of gastroenterology · 2017Review
- Current challenges in the treatment of severeTherapeutic advances in gastroenterology · 2017Review
- Stressor exposure has prolonged effects on colonic microbial community structure in Citrobacter rodentium-challenged mice.Scientific reports · 2017Article
- A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.Infectious diseases and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Antibiotics can play dual roles in Clostridium difficile infection (CDI); antibiotic treatment increases the risk of CDI, and antibiotics are used to treat CDI. The glycylcycline antibiotic tigecycline has broad antimicrobial activity, yet it is rarely associated with the development of CDI, presumably due to its activity against C. difficile. In this study, we investigated how tigecycline treatment affects the structure of the gut microbiota and susceptibility to CDI by treating mice with tigecycline (n = 20) or saline (n = 8) for 10 days. A sequence analysis of the bacterial 16S rRNA gene amplicons was used to monitor changes in the fecal microbiota. A subset of the mice was followed for 5 weeks after the end of treatment. The remaining mice were challenged with C. difficile strain VPI 10463 spores 2 days after the tigecycline treatment ended. Tigecycline treatment resulted in major shifts in the gut microbiota, including large decreases in Bacteroidetes levels and large increases in Proteobacteria levels. Mice with tigecycline-altered microbial communities were susceptible to challenge with C. difficile spores and developed clinical signs of severe CDI. Five weeks after the cessation of tigecycline treatment, the recovery of the bacterial community was incomplete and diversity was lower than in the untreated controls. Antibiotics with intrinsic activity against C. difficile can still alter the microbiota in a way that leads to susceptibility to CDI after discontinuation of the drug. These results indicate that microbiotic dynamics are key in the development of CDI, and a better understanding of these dynamics may lead to better strategies to prevent and treat this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.